A quantitative assay for tumor antigen based on inhibition of cytotoxicity of sensitized lymphocytes
β Scribed by Sally Huber; Zoltan J. Lucas
- Publisher
- John Wiley and Sons
- Year
- 1979
- Tongue
- French
- Weight
- 813 KB
- Volume
- 23
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Specific inhibition of cellβmediated cytotoxicity can be used as a quantitative measure of soluble tumor antigen if highly cytolytic cells are obtained. In vitro secondary stimulation of spleen cells sensitized in vivo to the syngeneic 13762A mammary adenocarcinoma results in a lymphocyte population consistently more cytolytic than lymphocytes after primary stimulation. Maximal cytolysis requires removal of dead lymphocytes from the effector population. Soluble tumor antigen (STA) is detected only in supernatant: of 13762A mammary tumor cultures grown in the presence of the proteolytic enzyme inhibitor, Ξ΅βamino caproic acid. Soluble MTM antigen preparations block lymphocytes immune to the mammary tumor but not lymphocytes immune to a second mammary adenocarcinoma (R3230) or to allogeneic spleen cells. Soluble antigen preparations from other tumors do not inhibit lymphocytes specifically cytolytic to the 13762A tumor. Additional evidence that the STA preparation contains tumor antigen is its ability to induce specific cytolytic lymphocytes and partial protection from challenge with live MTA tumor cells.
π SIMILAR VOLUMES
Cell locomotion and chemotaxis are usually assayed by the Boyden chamber technique, in which the response is measured by microscopical counting of the cells migrated into a micropore filter. We report a simplified Boyden chamber method which utilizes myeloperoxidase (MPO) specific to neutrophilic an
Common genetic variants significantly influence complex diseases such as primary biliary cirrhosis (PBC). We recently reported an association between PBC and a single nucleotide polymorphism (rs231725) of the immunoreceptor gene cytotoxic T-lymphocyte antigen 4 (CTLA4). We hypothesized that PBC risk